Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals is conducting a clinical study titled ‘A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels.’ The study aims to evaluate the effectiveness of combining fianlimab with cemiplimab and chemotherapy compared to the combination of cemiplimab and chemotherapy alone in treating advanced NSCLC.
The study is testing the investigational drug fianlimab, alongside cemiplimab and various chemotherapy agents like paclitaxel and carboplatin. These drugs are administered intravenously every three weeks to assess their impact on NSCLC treatment outcomes.
This interventional study is designed with a randomized, parallel assignment model and employs quadruple masking to ensure unbiased results. The primary purpose is treatment, focusing on the potential benefits of the drug combinations for NSCLC patients.
The study began on March 23, 2023, with an estimated primary completion date in 2025. The last update was submitted on August 29, 2025, indicating ongoing recruitment and data collection.
Regeneron’s study could significantly impact its stock performance, as successful results may enhance its competitive position in the oncology market. Investors should monitor developments closely, considering the broader industry context and potential shifts in market dynamics.
The study is currently ongoing, with further details available on the ClinicalTrials portal.